| http://www.w3.org/ns/prov#value | - PHILADELPHIA???(BUSINESS WIRE)???Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA?? (pembrolizumab), the company???s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs.
|
